Novel Light Delivery Method for Performing Transbronchial Photodynamic Therapy for Peripheral Lung Cancer

Launched by TAOYUAN GENERAL HOSPITAL · Feb 14, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to treat peripheral lung cancer using a technique called photodynamic therapy (PDT). PDT involves using light and special drugs to target tumors. The researchers are testing a method that uses a contrast agent called Lipiodol, which will be placed in the airways around the tumor during a procedure called bronchoscopy. This study aims to see if this new approach is safe and effective for patients with advanced lung cancer who have not responded to standard treatments like surgery or chemotherapy.

To participate in the trial, patients need to have a specific type of advanced lung tumor, which is 3 cm or smaller and can be seen on a CT scan. They must also have already tried other treatments without success or be unable to have those treatments. Participants will receive multiple light treatments aimed at the tumor, and they’ll be monitored closely throughout the study. It’s important for potential participants to know that certain conditions may exclude them from the trial, such as having specific types of lung cancer or recent treatments. Overall, this trial could help pave the way for better lung cancer therapies in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with advanced or terminal malignant lung tumors (including primary lung cancer and lung metastases from other cancers).
• • Patients who have failed standard treatments (surgery, radiotherapy, or first and second-line chemotherapy/immunotherapy/targeted therapy) or are unsuitable for standard treatments.
• • Tumor size less than or equal to 3 cm, clearly assessable on chest computed tomography.
• • Patients capable of providing informed consent and willing to undergo regular follow-ups during the trial.
• Exclusion Criteria:
• • Diagnosis of small cell lung cancer or non-solid malignancies.
• • Tumors located in the central part of the lungs.
• • Previous radiation therapy to the treatment site.
• • Abnormal blood biochemical values.
• • Chemotherapy received within the past 4 weeks.
• • Tumor invading major blood vessels.
• • Allergy to porphyrins or porphyrin-related metabolites, or allergy to Lipiodol or iodine-containing contrast agents.
• • Planning radical surgery for lung tumors within the next 90 days.
• • Potential need for slit lamp ophthalmic examination within the next 30 days due to existing eye diseases.
• • Inability to undergo bronchoscopy due to mental health conditions.
• • Pregnancy, planning pregnancy, breastfeeding, or planning to breastfeed within the next 6 months.
• • Previous photodynamic therapy within the past 1 month.
• • Severe kidney or liver disease with abnormal function.
• • Planning to participate in other cancer treatment clinical trials within the next 3 months.
• • HIV-positive patients.
• • Individuals deemed unsuitable for the trial by the principal investigator and the safety monitoring committee due to severe illnesses.